杨鲲,刘文娴,马琛明,吕树铮

• 1:首都医科大学附属北京安贞医院心内科监护室

摘要(Abstract)：

目的探讨冠心病患者阿司匹林抵抗(Aspirin resistance,AR)现象及其影响因素。方法入选1 731例入院诊断为冠心病(急性冠状动脉综合征和稳定型心绞痛)的患者。采用血小板聚集仪分别测定花生四烯酸(AA)、腺苷二磷酸(二磷酸腺苷,ADP)诱导的血小板聚集率。AR定义为0.5 mmol/L花生四烯酸时血小板平均聚集率≥20%,用10μmol/L ADP时血小板平均聚集率≥70%。阿司匹林半抵抗(Aspirin semiresistance,ASR)即符合上述两个条件之一者。均不符合者为阿司匹林敏感(Aspirin sensitive,AS)。用统计学方法分析各组间各项临床特征差异及影响AR与ASR的危险因素。结果1 731例患者中AR的发生率3.58%(62/1 731),ASR的发生率20.34%(352/1 731)。与AS相比,AR+ASR中以女性、高龄、高脂血症患者较多,吸烟者较少。而且AS患者的血小板计数偏高,总胆固醇水平偏低。Logistic回归分析表明,女性[相对比值比(OR)=1.377,95%可信区间(CI)1.084～1.751,P=0.009〗、老年(OR=1.504,95%CI1.005～2.253,P=0.047)、总胆固醇(TCHO)(OR=1.249,95%CI1.114～1.401,P=0.000)升高是发生AR与ASR的危险因素。结论服用阿司匹林的冠心病患者中AR发生率为3.58%,ASR发生率为20.34%。发生AR与ASR危险因素有女性、高龄、高血脂。

关键词(KeyWords)： 冠状动脉疾病;血小板聚集;阿司匹林抵抗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨鲲,刘文娴,马琛明,吕树铮

参考文献(References)：

• [1]Antithrombotic Trialists Collaboration.Collaborative meta-analy-sis of randomized trials of anti platelet therapy for prevention ofdeath,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86.
• [2]WeberA A,PrzytulskiB,SchanzA,et al.Towards a definition ofaspirin resistance:a typological approach.Platelets,2002,13:37-40.
• [3]Vejar M,Fragasso G,Hackett D,et al.Dissociation of plateletactivation and spontaneous myocardial ischemia in unstable angi-na.Thromb Headmost,1990,63:163-168.
• [4]Chyatte D,Chen TL.Patterns of failure of aspirin treatment insymtomatic atherosclerotic carotid artery disease.Neurosurgery,1990,26:565-569.
• [5]Buchanan MR,Brister SJ.Individual variation in the effects ofASA on platelet function:implication for the use of ASAclinical-ly.Can J Cordial,1995,11:221-227.
• [6]Metha J,Metha P,Burger C,et al.Platelet aggregation studies incoronary artery disease.Atherosclerosis,1978,31:169-175.
• [7]GumPA,Kottke-Marchant K,Poggio ED,et al.Profile and preva-lence of aspirin resistance in patients with cardiovascular disease.Am J Cordial,2001,88:230-235.
• [8]Macchi L,Christiaens L,Brabant S,et al.Resistance invitro tolow-dose aspirin is associated with platelet PlA1(GPⅢa)poly-morphism but with C807 T(GPⅠa/Ⅱa)and C-5T Kozak(GPⅠalpha)polymorphisms.J Am Coll Cardiol,2003,42:1115-1119.
• [9]Alexander JH,Harrington RA,Tuttle RH,et al.Prior aspirinuse predicts worse outcomes in patients with non-ST-elevation a-cute coronary syndromes.PURSUIT Investigators.PlateletⅡb/Ⅲa in Unstable angina:receptor suppression using integrilintherapy.Am J Cardiol,1999,83:1147-1151.
• [10]Andersen K,Hurlen M,Arnesen H,et al.Aspirin no respon-siveness as measured by PFA2100 in patient s wit h coronary ar-tery disease.Thromb Res,2002,108:37-42.
• [11]Helgason CM,Bolin KM,Hoff JA,et al.Development of aspirinresistance in persons with previous ischemic stroke.Stroke,1994,25:2331-2336.
• [12]Pulcinelli FM,Pignatelli P,Celestini A,et al.Inhibition ofplatelet aggregation by aspirin progressively decreases in long-term treated patients.J Am Coll Cardiol,2004;43:979-984.
• [13]Pulcinelli FM,Riondino S,Celestini A,et al.Persistent produc-tion of platelet thromboxane A2 in patients chronically treatedwith aspirin.J Thromb Haemost,2005,3:2784-2789.
• [14]Berglund U,Wallentin L.Persistent inhibition of platelet functionduring long-term treatment with 75mg acetylsalicylic acid daily inmen with unstable coronary artery disease.Eur Heart J,1991,12:428-433.
• [15]Simon Sanderson,Jon Emery,Trevor Baglin,et al.NarrativeReview:Aspirin Resistance and Its Clinical Implications.Ann In-tern Med,2005,142:370-380.
• [16]Pharand C,LordkipanidzéM,Palisaitis DA,et al.Aspirin re-sistance in stable coronary artery disease patients is associatedwith increased platelet turnover but not oxidative stress[J/OL].Arterioscler Thromb Vasc Biol,2007,27:e52[2009-04-21]http://atvb.ahajournals.org/cgi/reprint/27/6/e35?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=e-52+Arterioscler+Thromb+Vasc+Biol+June+2007&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT.
• [17]Ridker PM,Cook NR,Lee IM,et al.Arandomized trial of low-dose aspirin in the primary prevention of cardiovascular disease inwomen.N Eng J Med,2005,352:1293-1304.
• [18]Dalen JE.Aspirin resistance.Is it real?Is it clinically signifi-cant?Am J Med,2007,120:1-4.
• [19]Weber AA,Liesener S,Schanz A,et al.Habitual smoking cau-ses an abnormality in platelet thromboxane A2 metabolism and re-sults in an altered susceptibility to aspirin effects.Platelets,2000,11:177-182.
• [20]Lam JY,Lacoste L.Cigarette smoking acutely increasesplateletthrombus formation in patients with coronary artery disease takingaspirin.Circulation,1995,92:2432-2436.
• [21]Davis JW,Davis RF,Hassanein KM.In healthy habitual smokersacctylsalicyclic acid abolishes the effects of tobacco smoke on theplatelet aggregate ratio.Can Med Assoc J,1982,126:637-639.
• [22]Davis JW,Hartman CR,Lewis HD Jr,et al.Cigarette smokinginduced enchancement of platelet function:lack of prevention byaspirin in men with coronary artery disease.J Lab Clin Med,1985,105:479-483.
• [23]Maribeth F,Ivana V.Platelet responsiveness to aspirin in patientswith hyperlipidaemia.BMJ,2003,326:82-83.
• [24]Patrono C,Coller B,Dalen JE,et al.Platelet active drugs:therelationships among dose,effectiveness,and side effects.Chest,2001,119:39s-63s.